Get access

Obesity and obstructive sleep apnea-hypopnea syndrome

Authors

  • A. G. P. De Sousa,

    1. Obesity and Metabolic Diseases Group, Endocrinology and Metabology Service, Clinics Hospital, University of São Paulo Medical School, São Paulo, Brazil
    Search for more papers by this author
  • C. Cercato,

    1. Obesity and Metabolic Diseases Group, Endocrinology and Metabology Service, Clinics Hospital, University of São Paulo Medical School, São Paulo, Brazil
    Search for more papers by this author
  • M. C. Mancini,

    1. Obesity and Metabolic Diseases Group, Endocrinology and Metabology Service, Clinics Hospital, University of São Paulo Medical School, São Paulo, Brazil
    Search for more papers by this author
  • A. Halpern

    1. Obesity and Metabolic Diseases Group, Endocrinology and Metabology Service, Clinics Hospital, University of São Paulo Medical School, São Paulo, Brazil
    Search for more papers by this author

Errata

This article is corrected by:

  1. Errata: Corrigendum Volume 10, Issue 1, 143, Article first published online: 23 December 2008

AGP Sousa, Av Dr Eneas de Carvalho Aguiar 255, Instituto Central, 7° andar, Sala 7037, 05403–900, São Paulo, Brazil. E-mail: agpsousa@ig.com.br

Summary

Obstructive sleep apnea-hypopnea syndrome involves recurring episodes of total obstruction (apnea) or partial obstruction (hypopnea) of airways during sleep. Obstructive sleep apnea-hypopnea syndrome affects mainly obese individuals and it is defined by an apnea-hypopnea index of five or more episodes per hour associated with daytime somnolence. In addition to anatomical factors and neuromuscular and genetic factors, sleep disorders are also involved in the pathogenesis of sleep apnea. Obesity affects upper airway anatomy because of fat deposition and metabolic activity of adipose tissue. Obstructive sleep apnea-hypopnea syndrome and metabolic syndrome have several characteristics such as visceral obesity, hypertension and insulin resistance. Inflammatory cytokines might be related to the pathogenesis of sleep apnea and metabolic syndrome. Sleep apnea treatment includes obesity treatment, use of equipment such as continuous positive airway pressure, drug therapy and surgical procedures in selected patients. Currently, there is no specific drug therapy available with proven efficacy for the treatment of obstructive sleep apnea-hypopnea syndrome. Body-weight reduction results in improvement of sleep apnea, and obesity treatment must be emphasized, including lifestyle changes, anti-obesity drugs and bariatric surgery.

Ancillary